$16.19
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 30,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.
Country

US

CEO

Mr. Scott Smith

IPO date

1973

Employees

30,000

ISIN

US92556V1061

Key stats

Open

$16.38

Volume

9.21M

Market cap

$18.68B

Prev. close

$16.34

Impl / hst vl

-

Open interest

$0.00

$16.34

Day’s Range

$16.41

$12.19

52W Range

$17.53

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
1.31
P/B
1.31
Current ratio
1.60
Debt / Equity
0.86
ROE
-1.97%
Gross margin
39.18%
Income growth
-151.87%
FCF growth
-54.54

Jun

17

Dividends

The last payment date was Jun 17, 2026

Div. per Share

$0.12

Div. Yield

0.73%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Buy

The average rating from top 7 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$17.79
The top 11 analysts forecasts that 12-month price may increase by 9.91%, with a low of $12.12 and a high of $24.15
$12.12
Low
$17.79
Avg
$24.15
High
Current price

Earnings

Q1 ‘26 revenue
$3.52B
Q1 ‘26 net income
$176.40M
Revenue
Net income
Previous EPS
$0.59
Estimate EPS
$0.62
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply